Turvel (trovafloxacin)
- Region
- 🇪🇺 EU
- Active substance
- trovafloxacin
- Company
- Pfizer Limited
- Status
- Withdrawn
- Therapeutic area
- Bacterial Infections
- EU approval
- Wed 08 Jul 1998
- Application
- EMEA/H/C/000158
- ATC
- J01MA13
- Official record
- www.ema.europa.eu
Indication
Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults: Pneumonia: Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe). Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e.g. P. aeruginosa, has not been established. See also section 4.2. Acute Exacerbations of Chronic Bronchitis Acute Sinusitis Complicated Intra-abdominal Infections and Acute Pelvic Infections Salpingitis Uncomplicated Gonococcal Urethritis and Cervicitis Chlamydial Cervicitis Complicated Skin and Soft Tissue Infections Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Turvel IV Withdrawn · Pfizer Limited
- 🇪🇺 Trovan IV Withdrawn · Pfizer Limited
- 🇪🇺 Trovan Withdrawn · Pfizer Limited
Follow Turvel
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.